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Summary 
Background Trastuzumab duocarmazine is a novel HER2-targeting antibody–drug conjugate 
comprised of trastuzumab covalently bound to a linker drug containing duocarmycin. Preclinical 
studies showed promising antitumour activity in various models. In this first-in-human study, we 
assessed the safety and activity of trastuzumab duocarmazine in patients with advanced solid 
tumours. 
Methods We did a phase 1 dose-escalation and dose-expansion study. The dose-escalation cohort 
comprised patients aged 18 years or older enrolled from three academic hospitals in Belgium, the 
Netherlands, and the UK with locally advanced or metastatic solid tumours with variable HER2 status 
who were refractory to standard cancer treatment. A separate cohort of patients were enrolled to the 
dose-expansion phase from 15 hospitals in Belgium, the Netherlands, Spain, and the UK. Dose-
expansion cohorts included patients aged 18 years or older with breast, gastric, urothelial, or 
endometrial cancer with at least HER2 immunohistochemistry 1+ expression and measurable disease 
according to Response Evaluation Criteria in Solid Tumors (RECIST). Trastuzumab duocarmazine was 
administered intravenously on day 1 of each 3-week cycle. In the dose-escalation phase, trastuzumab 
duocarmazine was given at doses of 0·3 mg/kg to 2·4 mg/kg (3 + 3 design) until disease progression or 
unacceptable toxicity. The primary endpoint of the dose-escalation phase was to assess safety and 
ascertain the recommended phase 2 dose, which would be the dose used in the dose-expansion 
phase. The primary endpoint of the dose-expansion phase was the proportion of patients achieving 
an objective response (complete response or partial response), as assessed by the investigator using 
RECIST version 1.1. This ongoing study is registered with ClinicalTrials.gov, number NCT02277717, and 
is fully recruited.  
Findings Between Oct 30, 2014, and April 2, 2018, 39 patients were enrolled and treated in the dose-
escalation phase and 146 patients were enrolled and treated in the dose-expansion phase. One dose-
limiting toxic effect (death from pneumonitis) occurred at the highest administered dose (2·4 mg/kg) 
in the dose-escalation phase. One further death occurred in the dose-escalation phase (1·5 mg/kg 
cohort) due to disease progression, which was attributed to general physical health decline. Grade 3–
4 treatment-related adverse events reported more than once in the dose-escalation phase were 
keratitis (n=3) and fatigue (n=2). Based on all available data, the recommended phase 2 dose was set 
at 1·2 mg/kg. In the dose-expansion phase, treatment-related serious adverse events were reported 
in 16 (11%) of 146 patients, most commonly infusion-related reactions (two [1%]) and dyspnoea (two 
[1%]). The most common treatment-related adverse events (grades 1–4) were fatigue (48 [33%] of 
146 patients), conjunctivitis (45 [31%]), and dry eye (45 [31%]). Most patients (104 [71%] of 146) had 
at least one ocular adverse event, with grade 3 events reported in ten (7%) of 146 patients. No patients 
died from treatment-related adverse events and four patients died due to disease progression, which 
were attributed to hepatic failure (n=1), upper gastrointestinal haemorrhage (n=1), neurological 
decompensation (n=1), and renal failure (n=1). In the breast cancer dose-expansion cohorts, 16 (33%, 
95% CI 20·4–48·4) of 48 assessable patients with HER2-positive breast cancer achieved an objective 
response (all partial responses) according to RECIST. Nine (28%, 95% CI 13·8–46·8) of 32 patients with 
HER2-low, hormone receptor- positive breast cancer and six (40%, 16·3–67·6) of 15 patients with 
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HER2-low, hormone receptor-negative breast cancer achieved an objective response (all partial 
responses). Partial responses were also observed in one (6%, 95% CI 0·2–30·2) of 16 patients with 
gastric cancer, four (25%, 7·3–52·4) of 16 patients with urothelial cancer, and five (39%, 13·9–68·4) of 
13 patients with endometrial cancer. 
Interpretation Trastuzumab duocarmazine shows notable clinical activity in heavily pretreated 
patients with HER2-expressing metastatic cancer, including HER2-positive trastuzumab emtansine-
resistant and HER2-low breast cancer, with a manageable safety profile. Further investigation of 
trastuzumab duocarmazine for HER2-positive breast cancer is ongoing and trials for HER2-low breast 
cancer and other HER2-expressing cancers are in preparation. 
 
Introduction 
HER2 is a transmembrane tyrosine kinase receptor protein that promotes cell proliferation and inhibits 
apoptosis. HER2 overexpression, amplification, or both, is seen frequently across different tumour 
types1 and is associated with more aggressive disease and lower overall survival compared with 
cancers without HER2 overexpression.2,3 During the past two decades, multiple drugs targeting HER2 
have been developed for HER2-positive breast cancer, including (bispecific) antibodies, small 
molecules, vaccines, and antibody–drug conjugates. However, HER2-positive metastatic breast cancer 
is still incurable and eventual development of resistance to these treatments is almost inevitable.4,5 
Furthermore, trastuzumab did not improve the outcomes of patients with breast cancer expressing 
low amounts of HER2 (HER2-low), defined as HER2 immunohistochemistry (IHC) 1+ or IHC 2+ and in-
situ hybridization (ISH)-negative. Currently, no HER2-targeting drugs are licensed specifically for the 
treatment of any cancer with low expression of HER2. Therefore, new drugs that also target cancers 
with low HER2 expression will address an unmet need in several tumour types. 
Antibody–drug conjugates are designed for selective delivery of potent cytotoxic drugs to tumour cells 
by linking the cytotoxins to monoclonal antibodies. Trastuzumab emtansine, a HER2-targeting 
antibody–drug conjugate that contains trastuzumab covalently linked to a microtubule inhibitor, 
significantly prolonged progression-free survival and overall survival with acceptable toxicity in 
patients with HER2-positive metastatic breast cancer.6,7 Trastuzumab emtansine is currently 
recommended as second-line treatment for patients with breast cancer who have progressed after at 
least one line of trastuzumab-based treatment. Several new HER2-targeting antibody–drug conjugates 
with different linkers and payloads are currently in clinical development for multiple tumour types, 
with promising results.8,9  
Trastuzumab duocarmazine (also known as SYD985) is a novel HER2-targeting antibody–drug 
conjugate comprising the monoclonal IgG1 antibody trastuzumab covalently bound to a linker drug 
containing duocarmycin, with a drug-to-antibody ratio of 2・8:1.10–12 The linker drug contains a 
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cleavable linker and the prodrug seco-duocarmycin–hydroxybenzamide–azaindole (seco-DUBA). After 
binding to HER2 and internalization the linker is cleaved in the lysosome by proteases that release the 
active toxin (DUBA). The active toxin alkylates DNA, resulting in DNA damage in both dividing and non-
dividing cells and ultimately cell death. Additionally, proteases such as cathepsin B can be active 
extracellularly through secretion by malignant cells.13 Extracellular cleavage of the linker drug might, 
therefore, induce a bystander cell-killing effect that is not HER2-mediated.14 Trastuzumab 
duocarmazine has shown encouraging preclinical antitumour activity in breast, ovarian, and other 
cancers with varying (low to high) HER2 expression and was more potent than trastuzumab 
emtansine.12,15,16  
In this first-in-human study, we assessed the safety, pharmacokinetics, and preliminary antitumour 
activity of trastuzumab duocarmazine in patients with locally advanced or metastatic solid tumours. 
Here, we present data for the completed dose-escalation phase and safety and activity data for the 
fully recruited dose-expansion cohorts. 
 
Methods 
Study design and participants 
We did a phase 1 dose-escalation and dose-expansion study. Eligible patients were aged 18 years or 
older, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1, an estimated 
life expectancy of at least 12 weeks, and adequate organ function (see appendix pp 11–13 for full 
eligibility criteria). For the dose-escalation phase, patients were recruited from three academic 
hospitals in Belgium, the Netherlands, and the UK. Patients were eligible if they had locally advanced 
or metastatic solid tumours refractory to standard treatment, regardless of HER2 status. For the dose 
expansion phase, patients with HER2-expressing breast, gastric (including adenocarcinomas of the 
gastro-oesophageal junction), urothelial, or endometrial cancer were recruited from 15 hospitals in 
Belgium, the Netherlands, Spain, and the UK (appendix p 82). Eligible patients had to have at least one 
measurable tumour lesion as defined by Response Evaluation Criteria for Solid Tumours (RECIST) 
version 1.1, and centrally assessed tumour HER2 expression should have been at least IHC 1+.  
Key exclusion criteria for both study phases were anthracycline treatment within the previous 3 
months or any other cancer treatment within the previous 4 weeks; a history of infusion-related 
reaction, hypersensitivity to trastuzumab or trastuzumab emtansine, or both of these; left-ventricular 
ejection fraction (LVEF) less than 55%; severe uncontrolled systemic disease; and symptomatic brain 
metastases or treatment for brain metastases within 4 weeks. Further details can be found in the 
protocol (appendix pp 8–80).  
The study protocol, amendments, and informed consent forms were reviewed and approved by local 
authorities and independent ethics committees at each study site. All patients provided written 
informed consent before any protocol-related activities started. The study was done in accordance 
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with the Declaration of Helsinki and the International Conference on Harmonisation Good Clinical 
Practice guidelines.  
Procedures 
In the dose-escalation phase, trastuzumab duocarmazine (Synthon Biopharmaceuticals, Nijmegen, 
Netherlands) was administered intravenously on day 1 of each 3-week cycle with a first-in-human 
starting dose of 0・3 mg/kg. The first infusion was given over 1 h and, if well tolerated, subsequent 
infusions could be given over 30 min. We used a standard 3 + 3 dose-escalation design; doses were 
initially doubled for subsequent dose cohorts if no dose limiting toxic effect was recorded in the first 
treatment cycle. The definition of dose-limiting toxicity is provided in the appendix (p 1). If a dose-
limiting toxic effect was reported in one patient during the first cycle, at least three additional patients 
were to be treated at that dose level. Intrapatient dose escalation was not permitted, but dose 
reductions and delays were allowed by protocol (appendix pp 41–43). Patients were treated until 
disease progression or unacceptable toxicity. The highest dose level at which no more than one of six 
patients had a dose-limiting toxic effect was determined to be the maximum tolerated dose. The 
recommended phase 2 dose was determined based on all available safety, pharmacokinetic, and 
activity data. This dose was used in the dose-expansion phase.  
Patients in both study phases were assessed for toxicity at least once per week in the first two cycles 
and once during subsequent cycles, according to the National Cancer Institute Common Terminology 
Criteria for Adverse Events (NCI-CTCAE) version 4.03. Vital signs, haematology, blood chemistry, 12-
lead electrocardiograms (ECGs), cardiac biomarkers, and urinalysis were assessed at each visit. 
Weight, physical, and ophthalmological examinations, and LVEF assessments were done at each or 
every other cycle. Blood samples were obtained at each visit for pharmacokinetic assessment and 
before each infusion for immunogenicity analyses (measurement of antibodies against trastuzumab 
duocarmazine).  
After completion of the dose-escalation phase, several prophylactic measures were introduced, as per 
an approved protocol amendment (prepared and approved before the start of the dose-expansion 
phase in 2016), to assess the effect of trastuzumab duocarmazine on ocular toxicity. Lubricating eye 
drops were to be prescribed to all patients enrolled in the dose-expansion phase. Vasoconstrictive 
phenylephrine and anti-inflammatory dexamethasone eye drops were to be administered 1 h before 
the start of the infusion, and the anti-inflammatory dexamethasone eye drops were to be continued 
up to 2 days after infusion in the HER2-low breast cancer cohorts and in the non-breast cancer cohorts. 
In the HER2-positive breast cancer expansion cohort, patients were randomly allocated to either 1・2 
mg/kg every 3 weeks continuously, 1・2 mg/kg every 3 weeks for four cycles followed by 0・9 mg/kg 
every 3 weeks, or 1・2 mg/kg every 3 weeks for four cycles followed by 1・2 mg/kg every 6 weeks to 
investigate the effect of different dosing regimens on ocular toxicity. Randomisation was done in a 
1:1:1 ratio using a permutated block design with a block size of three. Allocation of subsequent 
patients was controlled centrally and communicated by the clinical research organisation (INC 
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Research, Amsterdam, Netherlands) to the investigators, who were to adjust the dosing schedule 
accordingly (dosing was open-label).  
HER2 tumour expression was assessed by IHC and ISH using archival or fresh tissue according to the 
American Society of Clinical Oncology and College of American Pathologists guidelines for breast and 
gastric cancer (appendix pp 47–49). Fresh tissue was obtained just before the start of study treatment 
if no archival tissue was available. HER2-positive disease was defined as IHC 3+ or ISH-positive. In the 
dose-escalation phase, tissue analysis was done by the local site laboratory, whereas in the dose-
expansion phase, tissue analysis was done centrally using HER2 IHC and dual ISH assays (Ventana; F 
Hoffmann-La Roche, Welwyn Garden City, UK). Patients with HER2 IHC 3+ or ISH-positive breast cancer 
were enrolled into the HER2-positive breast cancer cohort; patients with IHC 2+ or 1+ and ISH-negative 
breast cancer were enrolled in either the HER2-low hormone receptor positive cohort or the HER2-
low hormone receptor negative cohort so that we could assess these populations separately, in view 
of these patients’ substantially different biology, natural history, and treatment recommendations. 
Non-breast cancer cohorts included patients with HER2-low and HER2-positive tumours. Validated 
ELISA-based methods were used to measure the plasma concentration of total antibody (irrespective 
of the amount of conjugated toxins—ie, drug-to-antibody ratio ≥0) and conjugated antibody 
(antibodies that have at least one conjugated toxin—ie, drug-to-antibody ratio ≥1). A validated liquid 
chromatography–tandem mass spectrometry method was used for quantification of DUBA (free toxin) 
in plasma (appendix p 21).  
Tumour response was assessed by the investigator at baseline and every 6 weeks during treatment 
according to RECIST version 1.1, using CT, PET-CT, or MRI. 
Outcomes 
The primary endpoint of the dose-escalation phase was to assess safety and to ascertain the maximum 
tolerated dose and recommended phase 2 dose for trastuzumab duocarmazine. The primary endpoint 
of the dose-expansion phase was the proportion of patients who achieved an objective response 
(defined as either a complete response or a partial response, by RECIST 1.1). Secondary endpoints 
were safety, pharmacokinetics, immunogenicity, quality of life (data not reported here), and anti-
tumour activity. Anti-tumour activity endpoints were best percentage change in target lesion 
measurements, progression-free survival (defined as the time from first day of treatment to tumour 
progression or death from any cause), clinical benefit (the proportion of patients with a complete 
response, partial response, or stable disease for ≥6 months; data not reported here), duration of 
response (time from first observation of response to disease progression; data not reported here), 
and overall survival (time from treatment initiation to death from any cause; data not reported here). 
Statistical analysis 
We estimated that up to 24 patients (three to six patients per dose level) would need to be enrolled 
in the dose-escalation phase to ascertain the recommended phase 2 dose. In the dose-expansion 
phase, we initially estimated that up to 128 patients would be enrolled in six cohorts—ie, 48 patients 
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in the HER2-positive breast cancer cohort and 16 in each of the other five cohorts. A Simon’s two stage 
design was applied to all cohorts except for the HER2-positive breast cancer cohort. The null 
hypothesis that the true response was 5% or less was to be tested against the one-sided alternative 
of a response of 20%. In case the null hypothesis could be rejected—ie, if two or more responders 
were found in the initial 16 enrolled patients in a cohort—a maximum of 14 additional patients could 
be enrolled in that cohort for a total of 30 patients. This design had a type I error of 5% and a power 
of 80% when the true response was 20%.  
Safety and most of the activity endpoints were assessed in the safety population, which was defined 
as all patients who received at least one dose of study treatment. However, for the tumour response 
analysis, we excluded patients without measurable disease at baseline or without a post-baseline 
RECIST assessment. The population for pharmacokinetic analyses included all patients for whom at 
least one pharmacokinetic variable could be calculated. Descriptive statistics were used to summarise 
patients’ demographics, baseline characteristics, and safety data. Activity proportions were 
summarised with exact binomial 95% CIs. Progression-free survival was analysed using Kaplan-Meier 
quartile estimates and two-sided 95% CIs; data were censored either at the date of the last RECIST 
assessment when no documented date of progression (according to RECIST version 1.1) or death was 
available or when death or progression occurred after two or more consecutive missed assessments. 
Actual blood sampling times relative to the time of dose were used to ascertain pharmacokinetic 
variables. Values lower than the limit of quantification were imputed as zero. Statistical analyses were 
done with SAS version 9.4. Pharmacokinetic analyses were done with Phoenix WinNonlin version 8.1.  
This study is registered with ClinicalTrials.gov, number NCT02277717. 
Role of the funding source 
The funder contributed to study design, data collection, data analysis, data interpretation, and writing 
of the report. UB, CMLvH, ECM, NPK, and PA had full access to all the study data. The corresponding 
author had full access to all data in the study and had final responsibility for the decision to submit for 
publication. 
 
Results 
Between Oct 30, 2014, and April 2, 2018, 39 patients were enrolled and treated in the dose-escalation 
phase and 146 patients were enrolled and treated in the dose-expansion phase (figure 1). In the dose-
expansion phase, 50 patients had HER2-positive metastatic breast cancer, 32 had HER2-low hormone 
receptor-positive metastatic breast cancer, 17 had HER2-low hormone receptor negative metastatic 
breast cancer, 17 had gastric cancer, 16 had urothelial cancer, and 14 had endometrial cancer. At data 
cutoff (July 5, 2018), three patients with HER2-positive breast cancer, two patients with endometrial 
cancer, and one patient with urothelial cancer were still on treatment.  
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Median follow-up for all patients was 5・0 months (IQR 2・9–7・6) until the final safety assessment (July 
5, 2018). Patients’ demographics and baseline characteristics are provided in table 1 and the appendix 
(p 2). Patients were heavily pretreated with anticancer drugs, with a mean of 5・2 (SD 3・3) previous 
lines of treatment. In the HER2-positive metastatic breast cancer expansion cohort, 40 (80%) of 50 
patients had received previous trastuzumab emtansine.  
In the dose-escalation phase, initial doses of trastuzumab duocarmazine were doubled from 0・3 
mg/kg up to 2・4 mg/kg because no dose-limiting toxic effects occurred in the first treatment cycle. 
One of three patients dosed with 2・4 mg/kg trastuzumab duocarmazine developed pneumonitis in 
cycle 2, which was considered possibly related to the study drug, and after the third infusion this 
patient died. Although the event did not occur during the first cycle, it was considered a dose-limiting 
toxic effect. Because of the seriousness of this toxic effect and because promising activity was already 
seen at the 1・2 mg/kg dose level, the decision was made not to enrol three additional patients at the 
2・4 mg/kg dose but to assess lower doses in more detail. Therefore, the protocol-defined maximum 
tolerated dose of trastuzumab duocarmazine has not been defined. No dose-limiting toxic effects 
occurred at doses of 1・8 mg/kg (n=12), 1・5 mg/kg (n=12), or 1・2 mg/kg (n=6). The overall median 
duration of trastuzumab duocarmazine exposure was 3・5 months (IQR 1・4–5・4) and was longest at 
the 1・2 mg/kg dose (8・1 months [IQR 5・9–9・8] (appendix p 5).  
Treatment-related adverse events are shown in table 2 and divided per dose level in the dose-
escalation phase in the appendix (p 3). In the dose-escalation phase, grade 3 or grade 4 treatment-
related adverse events occurred in 13 (33%) of 39 patients (some patients had more than one event) 
and events reported more than once were keratitis (n=3) and fatigue (n=2). The most commonly 
recorded treatment-related adverse events of any grade in the dose-escalation phase were 
conjunctivitis (12 [31%] of 39 patients), fatigue (11 [28%]), and dry skin (ten [26%]). A reversible 
decrease in LVEF was reported as an adverse event for two (5%) of 39 patients, and for three (8%) 
patients, an absolute worst decrease in LVEF from baseline of at least 10% to a value below 50% was 
measured during treatment. One further patient in the 1・5 mg/kg cohort died in the dose-escalation 
phase (attributed to general physical health deterioration), which was related to disease progression. 
11 (28%) of 39 patients in the dose-escalation cohorts discontinued the study because of treatment-
related toxicity (three patients each in the 1・2 mg/kg and 1・5 mg/kg cohorts, four patients in the 1・
8 mg/kg cohort, and one in the 2・4 mg/kg cohort). Discontinuations were most commonly attributable 
to ocular adverse events after between five and ten cycles (n=5) or pneumonitis after between two 
and six cycles (n=4). Ocular toxicity improved after treatment discontinuation and was reported as 
recovered at the cutoff date for four patients. All four events of pneumonitis occurred at doses of 1・
5 mg/kg or higher and three events without respiratory symptoms (of which one was grade 1 and two 
were grade 2) resolved within 1 month after study discontinuation (the fourth event was the fatal 
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event described). Overall, doses up to 1・8 mg/kg were tolerated well without a clear dose-related 
occurrence of adverse events (appendix p 3), although ocular toxicity seemed to occur earlier at higher 
doses and increased with augmented exposure (data not shown). Based on these data, in combination 
with the observed treatment duration and activity data, the recommended phase 2 dose of 
trastuzumab duocarmazine was set at 1・2 mg/kg, because the 1・5 mg/kg and 1・8 mg/kg doses 
seemed not to improve the benefit:risk ratio for patients. The 1・2 mg/kg dose was used in the dose-
expansion cohorts.  
In the dose-expansion cohorts, the mean treatment duration was longest in the cohort with HER2-
positive breast cancer (mean 7・1 [SD 4・6] months). Mean treatment durations were similar in the 
cohorts with HER2-low hormone receptor-positive breast cancer (mean 3・7 [SD 2・3] months), HER2-
low hormone receptor negative breast cancer (3・3 [2・2] months), gastric cancer (3・2 [2・1] months), 
urothelial cancer (3・5 [2・2] months), and endometrial cancer (4・0 [2・8] months).  
The most common treatment-related adverse events of any grade in the dose-expansion cohorts were 
fatigue (48 [33%] of 146 patients), conjunctivitis (45 [31%]), and dry eye (45 [31%]; table 2). Grade 3 
or 4 treatment-related adverse events occurred in 51 (35%) of 146 patients and the most common of 
these were neutropenia (nine [6%]), fatigue (five [4%]), and conjunctivitis (four [3%]). 104 (71%) of 
146 patients had one or more ocular adverse events, with grade 3 events in ten (7%) of 146 patients. 
Occurrence of ocular toxic effects and their severity generally increased with prolonged exposure 
(data not shown), with a median time to grade 3 events of 7・6 months (IQR 4・3–8・9). Reduced dosing 
after four infusions of trastuzumab duocarmazine in patients with HER2-positive breast cancer—ie, 
either a decrease to 0・9 mg/kg every 3 weeks or to 1・2 mg/kg every 6 weeks—or use of prophylactic 
eye drops, or both of these, did not greatly improve tolerability, although several patients seemed to 
benefit (ie, toxicity remained stable or improved) from dose delays or dose reduction and could 
continue with trastuzumab duocarmazine treatment beyond 1 year (figure 2). Most ocular events 
improved or recovered with treatments such as eye drops or ointments, although recovery sometimes 
took several months. A decrease in LVEF was reported as an adverse event for 11 (8%) of 146 patients, 
of which eight were reported as resolved before data cutoff. In eight (5%) of 146 patients, an absolute 
worst decrease in LVEF from baseline of at least 10% to a value below 50% was measured during 
treatment. Treatment-related serious adverse events were reported in 16 (11%) of 146 patients, most 
commonly infusion-related reactions (two [1%]) and dyspnoea (two [1%]). Four patients died in the 
dose-expansion phase, one each from hepatic failure, upper gastrointestinal haemorrhage, 
neurological decompensation, and renal failure. These deaths were all related to disease progression 
and were not judged to be related to treatment. Overall, 62 (43%) of 146 patients had at least one 
treatment-related adverse event leading to one or more dose delays or dose reductions, and 27 (19%) 
of 146 patients discontinued the study because oftreatment-related toxic effects, of which 15 (10%) 
were attributable to ocular toxicity. Dyspnoea, decreased LVEF, and decreased appetite were each 
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reported for two (1%) patients as having contributed to treatment discontinuation; other reasons 
were reported as single events. Most of these events were reported as resolved at data cutoff.  
Total antibody, conjugated antibody, and DUBA (free toxin) pharmacokinetics after intravenous 
infusion of trastuzumab duocarmazine followed a monophasic log-linear decline and were time 
independent. Concentrations were generally close to or below the limit of quantification at 3 weeks 
after treatment at all dose levels, with minimal accumulation across consecutive cycles (appendix p 
4). Pharmacokinetics of all analytes were dose-proportional within the dose range of 1・2 mg/kg to 2・
4 mg/kg. Dose levels below 1・2 mg/kg had faster elimination of total and conjugated antibody, which 
is indicative of target-mediated drug disposition. Elimination half-life was 2–3 days for conjugated 
antibody at doses of 1・2 mg/kg or higher. Free toxin exposure was generally 3000 times lower 
compared with conjugated antibody (on a molar basis) with peak concentrations in the pg/mL range. 
Pharmacokinetic variables for conjugated antibody and DUBA (free toxin) are presented in the 
appendix (p 5). No patients were found to have antibodies against trastuzumab duocarmazine at any 
timepoint.  
In the dose-escalation phase, five of 39 patients were not assessable because of non-measurable 
disease (n=3) or a missing post-baseline RECIST assessment (n=2). Of the 34 assessable patients, 11 
(32%, 95% CI 17・4–50・5) had a partial response, of whom ten (six confirmed) had breast cancer and 
one (unconfirmed) had gastric cancer. Responses were seen in both HER2-positive and HER2- low 
tumours and all occurred at doses of 1・2 mg/kg or higher (figure 3A). Two patients (one with breast 
and one with other [duodenal] cancer) depicted in figure 3A had a partial response in target lesions 
but had progressive disease in non-target lesions at the same assessment.  
In the dose-expansion phase, six of 146 patients were not assessable because of a missing post-
baseline RECIST assessment (n=5) or non-measurable disease at baseline (n=1). In addition, for five of 
146 patients not all target lesions were assessed post baseline: these patients are included in the 
objective response analysis but are omitted from figure 3 on best percentage change in tumour size. 
In the three breast cancer expansion cohorts, 67 (71%) of 95 assessable patients showed a reduction 
in target lesions and 31 (33%) had a partial response, of which 23 were confirmed responses. An 
objective response (all partial responses) was achieved by 16 (33%, 95% CI 20・4–48・4) of 48 patients 
with HER2-positive breast cancer (figure 3B), nine (28%, 13・8–46・8) of 32 patients with HER2-low 
hormone receptor-positive breast cancer (figure 3C), and six (40%, 16・3–67・6) of 15 patients with 
HER2-low hormone receptor-negative breast cancer (figure 3D). Median progression-free survival was 
7・6 months (95% CI 4・2–10・9) in patients with HER2-positive breast cancer, 4・1 months (2・4–5・4) 
in patients with HER2-low hormone receptor-positive breast cancer, and 4・9 months (1・2–not 
estimable [NE]) in patients with HER2-low hormone receptor-negative breast cancer.  
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In the non-breast cancer expansion cohorts, 25 (57%) of 45 assessable patients had a reduction in 
target lesions (appendix pp 6, 7). An objective response (all partial responses) was achieved by one 
(6%, 95% CI 0・2–30・2) of 16 patients with gastric cancer, four (25%, 7・3–52・4) of 16 patients with 
urothelial cancer, and five (39%, 13・9–68・4) of 13 patients with endometrial cancer. Median 
progression-free survival was 3・2 months (95% CI 1・6–5・3) in patients with gastric cancer, 4・0 
months (1・3–NE) in patients with urothelial cancer, and 4・3 months (2・4–9・9) in patients with 
endometrial cancer.  
Of 50 patients with HER2-positive breast cancer in the dose-expansion phase, 28 (56%) received 
trastuzumab duocarmazine for longer than 6 months and seven (14%) were treated for longer than 1 
year (figure 2). Six of the seven patients with HER2-positive breast cancer treated for longer than 1 
year had previously received trastuzumab emtansine. 
 
Discussion 
To our knowledge, our phase 1 study in heavily pretreated patients with locally advanced or metastatic 
solid tumours is the first to report a novel antibody–drug conjugate with a DNA-alkylating duocarmycin 
payload. Trastuzumab duocarmazine showed a manageable safety profile with few grade 3 or 4 
adverse events. The recommended phase 2 dose was set at 1・2 mg/kg. Responses were noted across 
all tumour types, not only in HER2-positive tumours but also in tumours expressing lower levels of 
HER2.  
The side-effect profile of trastuzumab duocarmazine has both similarities and differences with other 
HER2-targeting antibody–drug conjugates. The most common side-effects seen with trastuzumab 
duocarmazine were attributable to ocular toxicity. Although such toxic effects have been described 
with other antibody–drug conjugates, they are less typical in HER2-targeting antibody–drug 
conjugates, and the pathophysiology of these events is not yet well understood.16 Planned dose 
reductions, decreasing the frequency of administration, or the use of prophylactic eye drops did not 
substantially change long-term tolerability of trastuzumab duocarmazine overall, but several patients 
were able to continue with study drug beyond 1 year and most ocular events were reported as 
recovered or improving at data cutoff. However, in view of the relative scarcity of data, additional 
observations—particularly over a prolonged treatment period—are necessary for drawing more 
definitive conclusions. Grade 3–4 thrombocytopenia was recorded in fewer than 1% of patients after 
treatment with trastuzumab duocarmazine, and grade 3–4 neutropenia was noted in 6% of patients—
frequencies that are lower than with other HER2-targeting antibody–drug conjugates. 7,17 This finding 
could be of importance when investigating future combination strategies. Pneumonitis was reported 
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as a dose-limiting toxic effect at the 2・4 mg/kg dose, but risk was diminished at the recommended 
phase 2 dose of 1・2 mg/kg. This type of adverse event has also been reported for both trastuzumab 
emtansine18 and trastuzumab deruxtecan—a HER2-targeting topoisomerase antibody–drug 
conjugate that is in development.17,19 However, the underlying mechanism or risk factor is not yet 
clear.  
The pharmacokinetic profile in combination with the DNA-alkylating mode of action of trastuzumab 
duocarmazine supports a dosing schedule of once every 3 weeks. Systemically free toxin levels were 
substantially lower compared with other antibody–drug conjugates such as trastuzumab emtansine20 
and trastuzumab deruxtecan.17 Amounts of antibody–drug conjugate achieved in patients are 
consistent with amounts achieved in mice, which showed significant xenograft growth delay with 
trastuzumab duocarmazine.12  
Our study has some limitations. First, we enrolled patients who had completed several late-line 
treatment options for metastatic disease. However, pertuzumab was not yet commonly prescribed 
for patients with HER2-positive breast cancer in Europe when the study started because of pending 
reimbursement discussions after approval of the drug in 2013, so fewer than half of the patients 
enrolled were pretreated with pertuzumab. Second, tumour assessments were not assessed centrally. 
Resulting estimates should be viewed with this limitation in mind but are nonetheless very 
encouraging in a phase 1 setting.  
Trastuzumab duocarmazine showed meaningful single-agent clinical activity in three areas of unmet 
need. First, relevant clinical activity was noted in patients with HER2-positive metastatic breast cancer, 
which is especially important because trastuzumab emtansine therapy is set to move to adjuvant 
treatment paradigms after the results of the KATHERINE study.21 Thus, the need for novel treatment 
options is increased for HER2-positive breast cancer in patients with metastatic disease after 
progression on trastuzumab emtansine. The TULIP randomised phase 3 study (NCT03262935) 
comparing trastuzumab duocarmazine with standard-of-care chemotherapy combinations in patients 
with HER2-positive breast cancer is ongoing. Second, activity of single-agent trastuzumab 
duocarmazine was also seen in patients with HER2-low (IHC 1+ or IHC 2+ ISH-negative) hormone 
receptor-negative disease, for whom no HER2-targeted drugs and antibody–drug conjugates are 
currently approved. These triple-negative breast cancers are a highly diverse group of cancers22 for 
which several antibody–drug conjugates targeting different antigens are in development. For 
example, the anti-TROP2 antibody–drug conjugate sacituzumab govitecan has shown encouraging 
activity in a phase 1 study.23 Moreover, the prolonged progression-free survival reported with 
atezolizumab in combination with nab-paclitaxel in a selective group of triple-negative patients is 
promising.24 Nevertheless, there is still a high unmet need to improve outcomes in these patients, and 
trastuzumab duocarmazine could potentially be of benefit in this setting. Third, trastuzumab 
duocarmazine showed some activity in non-breast HER2-expressing metastatic cancers, which have 
few treatment options and poor prognoses (eg, urothelial and endometrial cancers). Several 
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responses were noted in these patients, most of whom had HER2-low tumours. Although HER2 
expression data are variable between studies,1,25 further investigation of HER2-targeting drugs in this 
subset of patients would be worthwhile.  
In conclusion, this phase 1 study of trastuzumab duocarmazine has shown important and relevant 
clinical activity and a manageable safety profile in heavily pretreated patients with HER2-expressing 
metastatic cancer, including HER2-positive trastuzumab emtansine-resistant and HER2-low breast 
cancer. Further investigation of trastuzumab duocarmazine for HER2-positive breast cancer is ongoing 
in the phase 3 TULIP study to assess the efficacy and safety of trastuzumab duocarmazine compared 
with clinician’s choice in patients with locally advanced or metastatic breast cancer who progressed 
during or after at least two previous HER2-targeting treatment regimens or during or after 
trastuzumab emtansine. Additional studies to further investigate the encouraging signal from our 
phase 1 trial are in preparation. 
 
Research in context 
Evidence before this study 
We searched PubMed on Dec 20, 2018, for articles published in English, without restrictions on 
publication date, with the terms “metastatic breast cancer”, “HER2”, “antibody–drug conjugate”, and 
“ADC” in several combinations. We retrieved several publications in which treatment options beyond 
the first two lines of standard HER2-targeting treatment for metastatic breast cancer—ie, taxane plus 
trastuzumab plus pertuzumab followed by trastuzumab emtansine—consisted of various 
combinations of trastuzumab plus chemotherapy or the oral combination of lapatinib with 
capecitabine. These treatments generally resulted in a median progression-free survival of about 4 
months. No HER2-targeting drugs are currently licensed specifically for the treatment of breast or any 
other cancer with low HER2 levels. Antibody–drug conjugates can be regarded as targeted 
chemotherapy using a single agent and might provide a novel, potentially more effective, treatment 
option for these patients.  
Added value of this study 
To our knowledge, our study is the first to report the clinical profile of trastuzumab duocarmazine and 
its safety and activity in HER2-expressing metastatic breast and other cancers, including triple-
negative breast cancer.  
Implications of all the available evidence  
Trastuzumab duocarmazine warrants further investigation and might be a novel treatment option for 
patients with HER2-positive breast cancer who have been previously treated with trastuzumab plus 
pertuzumab or trastuzumab emtansine, or both. Our results suggest this HER2-targeting antibody–
drug conjugate should be investigated for patients with low levels of HER2-expression in multiple 
tumour types. 
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Table 1: Baseline characteristics  
 Dose-
escalation 
cohort 
(n=39) 
Dose-
expansion 
cohorts  
(n=146) 
HER2-
positive 
metastatic 
breast cancer 
(n=50) 
HER2-low, 
hormone 
receptor-positive 
metastatic breast 
cancer (n=32) 
HER2-low, 
hormone 
receptor-negative 
metastatic breast 
cancer (n=17) 
Non-breast 
cancer 
expansion 
cohorts 
(n=47) * 
Demographics 
Age (years) 55 (47-63) 57 (49-65) 54 (47-63) 53 (47-61) 53 (45-62) 64 (54-71)  
Sex  
  Female 
  Male 
 
30 (77%) 
9 (23%) 
 
120 (82%) 
26 (18%) 
 
50 (100%) 
0 
 
32 (100%) 
0 
 
17 (100%) 
0 
 
21 (45%) 
26 (55%) 
Race  
  White 
  Other 
 
38 (97%) 
1 (3%) 
 
140 (96%) 
6 (4%) 
 
47 (94%) 
3 (6%) 
 
32 (100%) 
0 
 
17 (100%) 
0  
 
44 (94%) 
3 (6%) 
Clinical characteristics 
ECOG performance status  
  0 
  1 
 
22 (56%) 
17 (45%) 
 
69 (47%) 
77 (53%) 
 
26 (52%) 
24 (48%) 
 
19 (59%) 
13 (41%) 
 
5 (29%) 
12 (71%) 
 
19 (40%) 
28 (60%) 
Time since initial diagnosis 
(months)  
67 (33-143) 53 (27-
100) 
78 (47-107) 94 (55-136) 43 (23-84) 25 (16-45) 
Cancer type 
  Breast 
  Gastric† 
  Colorectal 
  Urothelial 
  Endometrial 
  Other 
 
26 (67%) 
6 (15%) 
3 (8%) 
0 
1 (3%) 
3 (8%) 
 
99 (68%) 
17 (12%) 
0 
16 (11%) 
14 (10%) 
0 
 
50 (100%) 
0 
0 
0 
0 
0 
 
32 (100%) 
0 
0 
0 
0 
0 
 
17 (100%) 
0 
0 
0 
0 
0 
 
0 
17 (36%) 
0 
16 (34%) 
14 (30%) 
0 
Number of metastatic sites  3 (2-4) 3 (2-4) 3 (2-4) 3 (2-3) 3 (2-4) 3 (2-4) 
Known brain metastasis 3 (8%) 8 (5%) 5 (10%) 0 0 3 (6%) 
HER2 expression 
  Immunohistochemistry 3+ 
  Immunohistochemistry 2+ 
    ISH-positive 
    ISH-negative 
    ISH-equivocal 
    ISH-unassessable 
  Immunohistochemistry 1+ 
  Immunohistochemistry 0 
  Missing 
15 (39%) 
12 (31%) 
2 (5%) 
8 (20%) 
1 (3%) 
1 (3%) 
6 (15%) 
4 (10%) 
2 (5%) 
57 (39%) 
37 (25%) 
6 (4%) 
27 (18%) 
3 (2%) 
1 (1%) 
51 (35%) 
1 (1%) 
0 
41 (82%) 
3 (6%) 
3 (6%) 
0 
0 
0 
5 (10%)‡ 
1 (2%)‡ 
0 
0 
10 (31%) 
0 
10 (31%) 
0 
0 
22 (69%) 
0 
0 
0 
7 (41%) 
0 
7 (41%) 
0 
0 
10 (59%) 
0  
0 
16 (34%) 
17 (36%) 
3 (6%) 
10 (21%) 
3 (6%) 
1 (2%) 
14 (30%) 
0 
0 
Previous treatment 
Systemic treatments  
  1-3  
  4-6 
  >6 
6 (2-8) 
13 (33%) 
9 (23%) 
17 (44%) 
4 (3-7) 
50 (34%) 
55 (38%) 
41 (28%) 
6 (4-8) 
5 (10%) 
24 (48%) 
21 (42%) 
7 (5-9) 
3 (9%) 
11 (34%) 
18 (56%) 
4 (3-5) 
6 (35%) 
9 (53%) 
2 (12%) 
2 (2-3) 
36 (77%) 
11 (23%) 
0 
HER2 targeting treatment§ 
  Trastuzumab  
  Trastuzumab emtansine 
  Lapatinib 
  Pertuzumab 
20 (51%) 
20 (51%) 
16 (41%) 
9 (23%) 
2 (5%) 
62 (42%) 
61 (42%) 
43 (29%) 
26 (18%) 
17 (12%) 
47 (94%) 
46 (92%) 
40 (80%) 
23 (46%) 
15 (30%) 
6 (19%) 
6 (19%) 
3 (9%) 
2 (6%) 
2 (6%) 
1 (6%) 
1 (6%) 
0 
1 (6%) 
0 
8 (17%) 
8 
0 
0 
0 
CDK 4 or CDK6 inhibitors 2 (5%) 5 (3%) 0 5 (16%) 0 0 
PD-1 or PD-L1 inhibitors 0 14 (10%) 1 (2%) 2 (6%) 1 (6%) 10 (21%) 
Data are median (IQR) or n (%). ECOG=Eastern Cooperative Oncology Group. ISH=in-situ 
hybridisation. *Baseline characteristics by cancer type are in the appendix (p 2). †Gastric cancer 
including adenocarcinoma of the gastro-oesophageal juncƟon. ‡Tumour Ɵssue was HER2 ISH-
positive for these patients. §In the dose-expansion part of the study, patients with breast cancer 
were allocated to a cohort based on centrally assessed HER2 status on the most recent available 
tumour tissue, which in some patients deviated from previous locally assessed HER2 status. 
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Table 2: Adverse events considered related to trastuzumab duocarmazine 
Adverse Event 
Dose=escalation cohort (n=39) * Dose-expansion cohorts (n=146) 
Grade 1-2 Grade 3 Grade 4 Grade 1-2 Grade 3 Grade 4 
Fatigue 9 (23%) 2 (5%) 0 43 (29%) 5 (3%) 0 
Conjunctivitis 11 (28%) 1 (3%) 0 41 (28%) 4 (3%) 0 
Dry eye 6 (15%) 0 0 44 (30%) 1 (1%) 0 
Lacrimation increased 8 (21%) 0 0 29 (20%) 0 0 
Dry skin 10 (26%) 0 0 26 (18%) 0 0 
Decreased appetite 6 (15%) 1 (3%) 0 27 (18%) 2 (1%) 0 
Keratitis 3 (8%) 3 (8%) 0 25 (17%) 3 (2%) 0 
Alopecia 8 (21%) 0 0 26 (18%) 0 0 
Nausea 6 (15%) 0 0 27 (18%) 0 0 
Stomatitis 8 (21%) 1 (3%) 0 24 (16%) 0 0 
Skin hyperpigmentation 5 (13%) 0 0 23 (16%) 0 0 
Neutropenia 3 (8%) 1 (3%) 0 14 (10%) 9 (6%) 0 
Vomiting 5 (13%) 0 0 17 (12%) 0 0 
Anaemia 6 (15%) 1 (3%) 0 13 (9%) 2 (1%) 0 
Pyrexia 9 (23%) 0 0 9 (6%) 0 0 
Dysgeusia 7 (18%) 0 0 11 (8%) 0 0 
Infusion-related reaction 3 (8%) 0 0 13 (9%) 2 (1%) 0 
Vision blurred 0 0 0 15 (10%) 1 (1%) 0 
LVEF decreased 1 (3%) 1 (3%) 0 10 (7%) 1 (1%) 0 
Diarrhoea 1 (3%) 0 0 9 (6%) 1 (1%) 0 
Thrombocytopenia 2 (5%) 0 0 7 (5%) 1 (1%) 0 
Aspartate aminotransferase increased 1 (3%) 0 0 7 (5%) 1 (1%) 0 
Lymphopenia 0 0 0 7 (5%) 2 (1%) 0 
Dyspnoea 4 (10%) 0 0 2 (1%) 2 (1%) 0 
Asthenia 0 1 (3%) 0 7 (5%) 0 0 
Mouth ulceration 1 (3%) 0 0 5 (3%) 1 (1%) 0 
Pericardial effusion 0 1 (3%) 0 2 (1%) 2 (1%) 1 (1%) 
Gamma-glutamyltransferase increased 0 0 0 4 (3%) 0 2 (1%) 
Rash maculo-papular 1 (3%) 0 0 4 (3%) 1 (1%) 0 
Blood alkaline phosphatase increased 1 (3%) 0 0 3 (2%) 1 (1%) 0 
Pneumonitis 3 (8%) 0 0 0 0 1 (1%) 
Aminotransferase enzymes (not otherwise 
specified) increased 1 (3%) 0 0 3 (2%) 1 (1%) 0 
White blood cell count decreased 0 0 0 4 (3%) 1 (1%) 0 
Episcleritis 0 1 (3%) 0 4 (3%) 0 0 
Lymphocyte count decreased 0 0 0 1 (1%) 3 (2%) 0 
Platelet count decreased 0 0 1 (3%) 1 (1%) 2 (1%) 0 
Palmar-plantar erythrodysaesthesia 
syndrome 0 0 0 3 (2%) 1 (1%) 0 
Neutrophil count decreased 0 1 (3%) 0 2 (1%) 0 0 
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Hepatic enzyme increased 0 0 0 1 (1%) 1 (1%) 0 
Injection site reaction 0 1 (3%) 0 1 (1%) 0 0 
Pleural effusion 0 0 0 1 (1%) 1 (1%) 0 
Pancytopenia 0 0 0 0 1 (1%) 0 
Corneal toxicity not otherwise specified 0 0 0 0 1 (1%) 0 
Retinal haemorrhage 0 0 0 0 1 (1%) 0 
Ventricular dysfunction 0 0 0 0 1 (1%) 0 
Haemoptysis 0 0 0 0 1 (1%) 0 
Conjunctivitis bacterial 0 0 0 0 1 (1%) 0 
Pain in extremity 0 0 0 0 1 (1%) 0 
Delirium 0 0 0 0 0 1 (1%) 
Haematuria 0 0 0 0 1 (1%) 0 
Data are presented as n (%). Included in this table are maximum grade adverse events by preferred 
term deemed related to study drug. Grade 1 and 2 events are presented if they were recorded in at 
least 10% of all patients, and all grade 3 and 4 events are presented. One patient in the dose-
escalation cohort (2·4 mg/kg) died from pneumonitis that was deemed a dose-limiting toxicity; one 
further patient died (1·5 mg/kg) due to disease progression attributed to general health decline. No 
patients in the dose-expansion cohorts died from adverse events related to treatment; four patients 
died due to disease progression, which were attributed to hepatic failure (n=1), upper 
gastrointestinal haemorrhage (n=1), neurological decompensation (n=1), and renal failure (n=1). 
LVEF=left-ventricular ejection fraction. *Adverse events related to treatment by dose level are in the 
appendix (p 3). 
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Figure 1: Trial profile 
 
IHC=immunohistochemistry. ISH=in-situ hybridisation. *Three patients were added to the 1·2 mg/kg 
cohort at the same time that enrolment started for the 1·5 mg/kg cohort. †Cohort was expanded from 
16 to 32 patients when two of the initial 16 patients had a partial response (Simon two-stage design). 
‡PaƟents with HER2-positive metastatic breast cancer were randomly allocated to one of three 
different treatment subgroups to investigate the effect of different dosing regimens on ocular toxicity. 
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Figure 2: Duration of treatment for HER2-positive breast cancer expansion cohort 
 
Cross indicates the time of first partial response. Arrows indicate patients still on treatment at the 
cutoff date. All patients were treated with 1·2 mg/kg and were randomised to a lower dose (0·9 mg/kg) 
or longer interval (every 6 weeks) from cycle 5 (about 15 weeks) if dosing was not delayed. 
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Figure 3: Best percentage change in tumour size from baseline in target lesions for assessable 
patients 
(A) Dose-escalation phase, by cancer type, HER2 expression, and dose (in mg/kg). (B) Dose-expansion 
phase, HER2-positive breast cancer cohort. (C) Dose-expansion phase, HER2-low hormone receptor-
positive breast cancer cohort. (D) Dose-expansion phase, HER2-low hormone receptor-negative breast 
cancer cohort.  
Figure 3A: Dose-escalation phase, by cancer type, HER2 expression, and dose (in mg/kg) 
 
  
Manuscript version as published online for use on Institutional websites 
 
Figure 3B: Dose-expansion phase, HER2-positive breast cancer cohort 
 
Figure 3C: Dose-expansion phase, HER2-low hormone receptor-positive breast cancer cohort 
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Figure 3D: Dose-expansion phase, HER2-low hormone receptor-negative breast cancer cohort 
 
Dotted lines reflect 20% increase or 30% reduction in tumour size. Post-baseline target lesion 
assessment was incomplete for seven patients: three patients in (B), two patients in (C), and two 
patients in (D). HER2-low=low expression of HER2. G=gastric cancer including adenocarcinoma of the 
gastro-oesophageal junction. C=colorectal cancer. B=breast cancer. O=other cancer. *Best 
percentage change was 0%. 
